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Abstract  
We recently discovered that forebrain activation of the IL-1 receptor/Toll-like receptor (IL-
1R1/TLR4) innate immunity signal plays a pivotal role in neuronal hyperexcitability 
underlying seizures in rodents. Since this pathway is activated in neurons and glia in 
human epileptogenic foci, it represents a potential target for developing drugs interfering 
with the mechanisms of epileptogenesis that lead to spontaneous seizures. The lack of 
such drugs represents a major unmet clinical need. We tested therefore novel therapies 
inhibiting the IL-1R1/TLR4 signaling in an established murine model of acquired epilepsy. 
We used an epigenetic approach by injecting a synthetic mimic of micro(mi)RNA-146a that 
impairs IL1R1/TLR4 signal transduction, or we blocked receptor activation with 
antiinflammatory drugs. Both interventions when transiently applied to mice after epilepsy 
onset, prevented disease progression and dramatically reduced chronic seizure 
recurrence, while the anticonvulsant drug carbamazepine was ineffective. We conclude 
that IL-1R1/TLR4 is a novel potential therapeutic target for attaining disease-modifications 
in patients with diagnosed epilepsy.  
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Highlights 
• miR-146a hippocampal levels are transiently increased after injection of a synthetic 
oligonucleotide mimic. 
• miR-146a mimic reduces the levels of key proteins mediating the IL-1R1/TLR4 
signaling. 
• miR-146a mimic reduces neuronal excitability and acute seizures in mice. 
• miR-146a mimic and a combination of anti-inflammatory drugs, by targeting IL-
1R1/TLR4 arrest epilepsy progression and decrease chronic seizures in a mouse 
model of epilepsy. 
• CBZ did not display disease-modification effects 
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Abbreviations: AEDs, antiepileptic drugs; ANOVA, analysis of variance; AP-1, activator 
protein 1; BBB, blood brain barrier; CA,	Cornu Ammonis; COX-2, cyclooxygenase-2; CBZ, 
carbamazepine; EEG, electroencephalography; GABA, gamma-aminobutyric acid; 
HMGB1, High Mobility Group Box 1; IL-1β, interleukin-1β; IL-1R1, Interleukin-1 receptor 
type 1; intracerebroventricular, icv; IRAK-2, Interleukin-1 receptor-associated kinase-like 2; 
LNA, lock-nucleic-acid; miRNA, microRNA; NF-kB, nuclear factor kappa-light-chain-
enhancer of activated B cells; NMDA, N-methyl-D-aspartate; TLR4, Toll-like receptor 4; 
TRAF-6, TNF receptor associated factor 6;	SE, status epilepticus. 
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INTRODUCTION 
Epilepsy is a brain disorder affecting over 50 million people worldwide and is associated 
with increased mortality, significant comorbidities, unique stigmatization of affected 
individuals, and high societal cost (Duncan et al., 2006). Current antiepileptic drugs 
(AEDs) provide only symptomatic control of seizures, have multiple adverse effects, and 
are ineffective in up to 40% of patients (Weaver and Pohlmann-Eden, 2013). This 
represents a major unmet clinical need. To bridge the treatment gap, next generation 
therapies need to possess disease-modifying properties by targeting the mechanisms 
intimately involved in making the brain susceptible to generate spontaneous seizures. 
Such drugs are still lacking and they could potentially be used to halt or reverse the 
progression of epilepsy in patients with an established diagnosis, or delay or prevent the 
onset of epilepsy in susceptible individuals (Barker-Haliski et al., 2015).   
 Experimental evidence shows that the activation of the IL-1 receptor/Toll-like 
receptor (IL-1R1/TLR4) pathway is a major pathogenic factor in epilepsy since its 
pharmacological or genetic inactivation dramatically reduces seizure recurrence in 
experimental models of either acute seizures or established epilepsy (Ravizza et al, 2006; 
Vezzani et al., 2000; Vezzani et al., 2002; Balosso et al., 2008; Maroso et al., 2010; 
Maroso et al., 2011a; Vezzani et al., 2011b; Iori et al., 2013; Balosso et al., 2014). Notably, 
this pathway is activated in neurons and glia in epileptogenic foci surgically resected in 
patients affected by various forms of acquired pharmacoresistant epilepsy (Vezzani et al., 
2011a).  
Different epileptogenic insults imposed to mice or rats (e.g., neurotrauma, stroke, infection, 
febrile and non-febrile status epilepticus) trigger a rapid and long-lasting IL-1R1/TLR4 
activation in seizure-prone brain areas (Vezzani et al., 2011b; Vezzani et al., 2013) 
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mediated by the release of interleukin(IL)-1β and danger signals, such as High Mobility 
Group Box 1 (HMGB1), from glia, neurons and cellular components of the blood brain 
barrier (BBB). The activation of IL-1R1/TLR4 pathway in receptor-expressing neurons 
promotes excitotoxicity and seizures by enhancing calcium influx via N-methyl-D-aspartate 
(NMDA) receptors (Viviani et al., 2003; Balosso et al., 2008; Pedrazzi et al., 2012; Iori et 
al., 2013; Balosso et al., 2014). Activation of IL-1R1/TLR4 in glial cells induces a 
neuroinflammatory cascade by transcriptional activation of NF-κB and AP-1 sensitive 
genes, including cytokines, chemokines, COX-2 and complement factors (Vezzani et al., 
2011b; Vezzani et al., 2015b). The extent and persistence of these molecules in brain are 
key determinants of the switch from the homeostatic role of neuroinflammation to its 
contribution to cell damage and dysfunction (Heinemann et al., 2012; Devinsky et al., 
2013). The link between IL-1R1/TLR4 signaling activation, neuronal hyperexcitability and 
reduction of seizure threshold may potentially contribute to the development of a chronic 
epileptogenic network ignited by different brain insults. This pathway therefore represents 
a potential target for attaining disease-modifications in epilepsy, thereby improving disease 
prognosis. 
 In this study, we tested the potential therapeutic effects, based on disease 
modifications, of epigenetic or pharmacological interventions designed for inhibiting the 
IL1R1/TLR4 pathway activation in a widely used mouse model of acquired epilepsy 
(Shinoda et al., 2004; Li et al., 2008; Mouri et al., 2008; Jimenez-Mateos et al., 2012; Liu 
et al., 2013; Gu et al., 2015). Epigenetic intervention was based on micro(mi)RNA brain 
delivery. miRNAs are small non-coding RNA that represent key epigenetic 
posttranscriptional regulators of cellular protein levels (Jimenez-Mateos et al, 2013).  
Specifically, we selected to enhance the negative feed-back regulation of the IL-1R1/TLR4 
signaling mediated by miR-146a (Taganov et al., 2006; O'Neill, 2008; Boldin et al., 2011; 
Quinn and O'Neill, 2011; Iyer et al., 2012; Zeng et al., 2013; van Scheppingen et al., 2016) 
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using a synthetic oligonucleotide mimic. Notably, miR146a is induced in neurons and glia 
in both experimental and human epilepsy (Aronica et al., 2010; Quinn and O'Neill, 2011; 
Omran et al., 2012; Prabowo et al., 2015; van Scheppingen et al., 2016). In 
complementary studies, we used a combination of antiinflammatory drugs for effectively 
blocking IL-1R1/TLR4 activation. We applied these agents for a limited period of time after 
the onset of epilepsy in mice to simulate a clinical intervention in patients with diagnosed 
epilepsy. 
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MATERIALS AND METHODS 
Animals 
We used 8 week-old C57BL6N male mice (~23-30 g) in all experiments, except for 
electrophysiological recordings that were done in 21 day-old C57BL6N male mice (Charles 
River, Calco, Italy). Mice were maintained in SPF facilities at the Mario Negri Institute and 
housed at a constant room temperature (23°C) and relative humidity (60 ± 5%) with free 
access to standard food pellet (2018S, Envigo, Udine, Italy) or to CBZ-in-food and its 
control pellet (BioServe, F05572; Frenchtown, NJ, USA; Grabenstatter et al, 2007) and 
water, and with a fixed 12 h light/dark cycle. Mice were housed 5 animals per cage. After 
experimental manipulations (as reported below) each mouse was individually housed in 
the presence of environmental enrichment (i.e. toilet paper, straw).  
Study design 
In this study we investigated the potential therapeutic effects of epigenetic or 
pharmacological targeting of the IL-1R1/TLR4 pathway in an established mouse model of 
acquired epilepsy. Drugs were therefore transiently applied after the onset of epilepsy in 
each mouse, as determined by the occurrence of the first two video-EEG recorded 
spontaneous seizures at least 48 h after status epilepticus (SE) was elapsed. Treatment 
schedule was determined according to pharmacokinetic and pharmacodynamic data, as 
specified in each treatment protocol. 	
Data are presented as mean ± SEM and are inclusive of all mice that were randomized in 
the biochemical or therapeutic studies. No animal was excluded from the study except for 
mice which did not develop SE (8 out of 88) due to kainate injection misplacement. The 
number of mice in each experiment is indicated by n values in the figure legends, methods 
and supplementary materials. In each experiment, simple randomization was used as 
treatment allocation rule; blinding was applied to treatment administration and data 
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analysis. In the proof-of-concept studies in Figs 1, 2 and 3, animal sample size was 
estimated empirically on the basis of our previous experience with the epilepsy models 
and the therapeutic effects of anti-inflammatory drugs (Vezzani et al., 2000; Balosso et al., 
2008; Maroso et al., 2010; Maroso et al., 2011a; Iori et al., 2013; Balosso et al., 2014). Our 
primary endpoint was ≥50% reduction in the frequency of seizures at the end stage of the 
disease (i.e. 2.5 months after epilepsy onset) in the treated group compared to the 
respective control group. We also took into careful consideration the principles of the 3 Rs 
(Replacement, Reduction and Refinement; https://www.nc3rs.org.uk/the-3rs). All 
experimental procedures were conducted in conformity with institutional guidelines that are 
in compliance with national (D.L. n.26, G.U. March 4, 2014) and international guidelines 
and laws (EEC Council Directive 86/609, OJ L 358, 1, December 12, 1987, Guide for the 
Care and Use of Laboratory Animals, U.S. National Research Council, 1996), and were 
reviewed and approved by the intramural ethical committee. 
Intracerebroventricular injections of oligonucleotides 
Mice were surgically implanted under general gas anesthesia (1-3% isoflurane in O2) and 
stereotaxic guidance (Maroso et al., 2010; Iori et al., 2013) with a guide cannula positioned 
on top of the dura mater (from bregma, mm: nose bar 0; anteroposterior 0, lateral 0.9) 
(Franklin and Paxinos, 2008) one week before the injections. miR-146a mimic (Applied 
Biosystems, Carlsbad, CA, USA), antagomiR LNA (Superior probes, RiboTaskApS, 
Odense, Denmark) or their respective controls (specific random sequence for mimic or 
negative control with no effects on known miRNA function; Applied Biosystems; see table 
below) were dissolved in sterile PBS and injected intracerebroventricularly (icv, 0.25 
µl/min) in freely moving mice over 4 min using a 30-gauge injection needle connected to a 
10.0 µl Hamilton microsyringe via PE20 tubing, according to convection-enhanced delivery 
	 9	
method (Gasior et al., 2007). At the end of infusion, the needle was left in place for one 
additional minute to avoid backflow through the guide cannula, then gently removed.  
The mimic or its negative control were administered icv as single injection (5 or 10 µg in 1 
µl; Fig. 1A,B; Fig. S1; Fig. S2, panels a-f) or repetitively (10 µg in 1 µl; one injection every 
three days for a total of five injections; Fig. 2; Fig. S2, panels g-o; Fig. S3D) while the 
antagomiR or its negative control was injected icv twice a day for six consecutive days 
(Krutzfeldt et al., 2005) (1 µg in 1 µl; Fig. 1C,D).  
 
Modulation of miR-146a levels. For RT-qPCR analysis of hippocampal levels of miR-146a 
(Fig. 1A,C), the mimic (n=8) or its antagomiR (n=10) or their respective negative controls 
(n=8-10 each group) were injected in naïve mice that were killed 24 h or 72 h later. For in 
situ hybridization analysis of forebrain miR-146a levels, mice (electrode implanted but not 
exposed to SE; Sham) were injected with a single injection of mimic or its negative control 
(n=5 each group) and killed 24 h later (Fig. S2). A different cohort of SE-exposed mice 
were injected with mimic or its negative control (n=4-5 each group) using the repetitive 
injection protocol used for assessing the disease-modification effect of the treatment (Fig. 
S2; protocol in Fig. S3B), and mice were killed 24 h after the last injection.  
Effect of miR-146a on neuronal excitability and acute seizure in naive mice. In the model 
of acute seizures, different groups of mice were injected icv, ipsilaterally to kainate or 
bicuculline injection, with a single mimic, or negative control, injection at different time 
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points (i.e., 1 h, 24 h, 72 h or 7 days) before intrahippocampal kainic acid, or 24 h before 
intrahippocampal bicuculline (n=6-10 each group) (protocol in Fig. S4B). A cohort of mice 
similarly injected with mimic- or negative control (n=5-7 each group) was used for testing 
neuronal excitability in acute hippocampal slices, 24 h after injection (Fig. S1E). A different 
group of naive mice (n=6 each group) received repetitive mimic or negative control 
injections (one injection every three days for a total of five injections; protocol in Fig. S4C), 
then 24 h or 7 days after the last injection, mice received intrahippocampal kainate (Fig. 
S3D). The time-dependent effect of mimic on acute seizures was used as a 
pharmacodynamic measure of its tissue clearance. 
miR-146a effect on disease progression. In the model of SE-induced epilepsy, 10 µg of 
mimic or its negative control was injected icv (ipsilateral to intra-amygdala kainate 
injection) in mice at day 1 (onset of epilepsy) and at day 4, 7, 10, 13 thereafter (repetitive 
injection protocol, Fig. S3B), then treatment was stopped (n=15 each group).  
Mouse model of acute symptomatic seizures 
Mice (n=128) were surgically implanted under general gas anesthesia (1-3% isoflurane in 
O2) and stereotaxic guidance (Maroso et al., 2010; Iori et al., 2013). Two nichrome-
insulated bipolar depth electrodes (60 µm OD) were implanted bilaterally into the dorsal 
hippocampus (from bregma, mm: nose bar 0; anteroposterior –1.8, lateral 1.5 and 2.0 
below dura mater) (Franklin and Paxinos, 2008). A 23-gauge guide cannula was 
unilaterally positioned on top of the dura mater and glued to one of the depth electrodes 
for the intrahippocampal injection of kainic acid or bicuculline methiodide. One additional 
guide cannula was positioned on top of the dura mater (from bregma, mm: nose bar 0; 
anteroposterior 0, lateral 0.9) (Franklin and Paxinos, 2008) ipsilateral to the 
intrahippocampal injection for icv injections of either miR-146a mimic, its antagomiR, or the 
respective negative controls (protocols in Fig. S4B). Two screw electrodes were positioned 
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over the nasal sinus and the cerebellum, and used as ground and reference electrodes, 
respectively. The electrodes were connected to a multipin socket and, together with the 
injection cannula were secured to the skull by acrylic dental cement. The top of each cage 
had a commutator, which allows the recording cable attached to the multipin socket 
anchored to the mouse head to swivel freely. The commutator is connected to a data 
acquisition set up that collects the EEG data from each mouse, and send them to a 
computer where the EEG tracing can be displayed on the screen and stored for later 
analysis. Intrahippocampal injection of kainic acid or bicuculline was done in freely moving 
mice, 7 days after surgery (Maroso et al., 2010; Iori et al., 2013). The drugs (kainic acid 7 
ng in 0.5 µl; bicuculline methiodide 51 ng in 0.5 µl; Sigma-Aldrich, Saint Louis, MO, USA) 
were dissolved in 0.1 M phosphate-buffered saline (PBS, pH 7.4) and injected (in 30 sec) 
unilaterally in the dorsal hippocampus in lightly restrained mice by using a needle 
protruding 2.0 mm from the bottom of the guide cannula (Fig. S4A). The needle was left in 
place for one additional minute to avoid backflow through the guide cannula, then removed 
and mice were freely moving for the rest of the experiment. Doses of kainic acid and 
bicuculline were chosen to induce EEG ictal episodes in the hippocampus in 100% of mice 
without mortality. These seizures are sensitive to both anti-inflammatory treatments and 
genetic manipulation of inflammatory pathways (Vezzani et al., 2000; Balosso et al., 2008; 
Maroso et al., 2010; Maroso et al., 2011b; Iori et al., 2013).  
Acute seizure assessment and quantification have been extensively described before 
(Balosso et al., 2008; Maroso et al., 2010; Maroso et al., 2011a; Iori et al., 2013; Balosso 
et al., 2014). Briefly, a 30 min EEG recording was done before kainic acid or bicuculline 
injection to assess baseline activity, and for 180 min after the drug injection. At least 30 
min EEG recording similar to baseline was required before ending the experiment. Ictal 
episodes (Fig. S4A) are characterized by high-frequency (7-10 Hz) and/or multispike 
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complexes and/or high-voltage (700 µV-1.0 mV vs 100-300 µV during pre-injection 
baseline) synchronized spikes simultaneously occurring in the injected and contralateral 
hippocampi, lasting 50 sec on average. Seizure activity was quantified by measuring the 
onset time elapsed from kainic acid or bicuculline injection to the occurrence of the first 
EEG seizure and the number and total duration of seizures (reckoned by summing up the 
duration of each ictal episode during the EEG recording period). Seizures occurred with an 
average latency of about 10 min from kainic acid or bicuculline injection, then recurred for 
about 120 min from their onset, and were associated with motor arrest of the mice. At the 
end of the experiment, mice were killed by decapitation under deep penthotal sodium (100 
mg/kg, i.p.) anaesthesia, and the correct positioning of the injection needle and electrodes 
was verified in 40 µm cryostat sections from post-mortem frozen brains. 
Mouse model of SE-induced epilepsy 
Mice (n=88) were surgically implanted under general gas anesthesia (1-3% isoflurane in 
O2) and stereotaxic guidance. A 23-gauge guide cannula was unilaterally positioned on top 
of the dura mater for the intra-amygdala injection of kainic acid (from bregma, mm: nose 
bar 0; anteroposterior-1.06, lateral -2.75) (Franklin and Paxinos, 2008) (Fig. S3A). In mice 
reported in Fig. 2 (n=15), Fig. 3A,B (n=22) and Fig. S2, panels g-o (n=8), a nichrome-
insulated bipolar depth electrode (60 µm OD) was implanted in the dorsal hippocampus 
(from bregma, mm: nose bar 0; anteroposterior –1.8, lateral 1.5 and 2.0 below dura mater) 
(Franklin and Paxinos, 2008) ipsilateral to the injected amygdala and a cortical electrode 
was placed onto the somatosensory cortex in the contralateral hemisphere. In different 
cohorts of mice (n=23) included in Fig. 2 (n=16) and in Fig. 3C (n=7), the cortical electrode 
was substituted by a recording bipolar electrode in the injected amygdala. We used these 
different recordings sites in order to determine if EEG seizures simultaneously occur in 
hippocampus, cortex and injected amygdala, and to assess the effect of treatments. Ictal 
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activity was always associated with generalized motor convulsions. Seven additional mice 
were similarly implanted and received CBZ-placebo pellet (see legend Fig. 3). In all mice, 
two screw electrodes were positioned over the nasal sinus and the cerebellum, and used 
as ground and reference electrodes, respectively. Additionally, in mice depicted in Fig. 2 
and in Fig. S2, one guide cannula was positioned on top of the dura mater (from bregma, 
mm: nose bar 0; anteroposterior 0, lateral 0.9) (Franklin and Paxinos, 2008) ipsilateral to 
the injected amygdala for icv injection of 10 µg miR-146a mimic or its negative control. 
Electrodes were connected to a multipin socket (PlasticOne Inc., USA). One week after 
surgery, mice were connected to the video-EEG set up and a 60 min baseline recording 
was done before inducing SE.  
SE induction. Kainic acid (0.3 µg in 0.2 µl) was unilaterally injected in the basolateral 
amygdala in freely moving mice (n=88) using a needle protruding of 3.9 mm below the 
implanted cannula (Fig. S3A). SE developed after approximately 10 min from kainic acid 
injection, and was defined by the appearance of continuous spikes with a frequency >1.0 
Hz. Spikes were defined as sharp waves with an amplitude at least 2.5-fold higher than 
baseline and lasting <20 msec, or as a spike-and-wave with a duration of <200 msec 
(Frigerio et al., 2012). The end of SE was determined by inter-spike interval >2 sec. After 
40 min from SE onset, mice received diazepam (10 mg/kg, intraperitoneally, i.p.) to 
improve their survival rate. SE was successfully evoked in 80 out of 88 mice, and it lasted 
for 8.1 ± 0.5 h. Six mice died within few hours up to 3 days after SE induction, therefore 74 
mice were used for the subsequent experiments. The total number of spikes was 
measured in mice during the first 12 h after kainic acid administration (Suppl. Fig. 3C; 
Clampfit 9.0, Axon Instruments, Union City, CA, U.S.A).  
Animal use. Thirty SE-exposed mice were used for testing the effect of miR-146a mimic vs 
its negative control (n=15 each group) on spontaneous seizure progression and frequency 
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(Fig. 2). Twenty-nine mice were used for testing the effect of pharmacological treatments 
on spontaneous seizure progression and frequency: 22 mice were injected with VX-
765+CyP or their vehicles (n=11 each group; Fig. 3A,B) and 7 mice were treated with 
CBZ-in-food (Fig. 3C). Seven SE-exposed mice were fed with CBZ placebo pellet. Eight 
SE-exposed mice were used for in situ hybridization analysis of miR-146a (Fig. S2).  
Chronic seizures assessment and quantification, and treatment schedule. Spontaneous 
seizure development after SE has been described before (Mouri et al., 2008; Jimenez-
Mateos et al., 2012; Liu et al., 2013; Gu et al., 2015). Spontaneous generalized motor 
seizures develop 5.3 ± 0.2 days after SE (n=59 including treated mice and their controls; 
Figs. 2 and 3). In negative control- or vehicle- injected mice, the daily number of seizures 
remains relatively stable for the first 45 days after epilepsy onset, then seizure frequency 
increases by about 3-fold reaching a stable baseline thereafter (Fig. S3B, n=26). All mice 
were video-EEG recorded continuously (24/7) from the onset of SE until the onset of 
epilepsy (i.e., two unprovoked spontaneous seizures occurring at least 48 h from the end 
of SE). After the onset of epilepsy in each mouse, animals were randomized in control and 
treatment groups (treatment protocols are described in Fig. S3B) and injected with 10 µg 
mimic or its negative control (n=15 each group) (Fig. 2), or with a combination of the 
clinically used drug VX-765, a selective inhibitor of Interleukin Converting 
Enzyme/Caspase-1 which blocks both IL-1β biosynthesis (Wannamaker et al., 2007) and 
HMGB1 release (Keyel, 2014) (100 mg/kg, ip, dissolved in deionized H202 containing 0-5% 
HEC and 0.1% Tween-80) and the investigational drug Cyanobacterial LPS, a TLR4 
antagonist (Macagno et al., 2006; Maroso et al., 2010) (CyP, 1 mg/mouse, ip,  dissolved in 
saline) or their respective vehicles (n=11 each group; Fig. 3A,B); or mice were fed with 
CBZ-in-food (5 mg/g pellet; 20 mg/daily/mouse; n=7; Fig. 3C). Video-EEG was 
continuously recorded (24/7) during treatment time (which differs depending on the 
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protocol, see Fig. S3B), then mice were temporarily disconnected from the EEG set up, 
and left in their home cage until they were again monitored (24/7) starting from day 45 
after epilepsy onset until day 74 (Fig. S3B; Figs. 2 and 3). One group of mimic- or negative 
control-treated mice (n=7 out of 15 each group) was EEG recorded from day 60 until day 
74 (Fig. 2). Spontaneous seizures are EEG paroxysmal events lasting 30-60 sec on 
average and simultaneously occurring in amygdala, hippocampus and fronto-parietal 
cortex, bilaterally (Fig. S3A). EEG seizures were always accompanied by generalized 
motor convulsions as assessed using WFL-II/LED15W infrared video-cameras (Videor 
Technical, GmbH, Germany) syncronized with the EEG recording system. We reckoned 
the total number of spontaneous seizures during the recording period, and divided them by 
the total number of recording days, in order to estimate the number of daily seizures (Figs. 
2 and 3). EEG activity was recorded using the Twin EEG Recording System (version 
4.5.3.23) connected with a Comet AS-40 32/8 Amplifier (sampling rate 400 Hz, high-pass 
filter 0.3 Hz, low-pass filter 70 Hz, sensitivity 2000 mV/cm; Grass-Telefactor, West 
Warwick, R.I., USA). Digitized video-EEG data were processed using the Twin record and 
review software. EEG analysis in acute and chronic models was done by two independent 
investigators blinded to the treatment, who visually reviewed all the EEG tracings. 
Deviation of ≤5% from concordance was considered acceptable; otherwise EEG tracing 
was additionally analyzed by a third person. 
One additional experimental group consisted of mice with electrode and cannula implanted 
under the same surgical conditions as described above. These mice were not exposed to 
SE and were used as sham controls where appropriate.  
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Histological evaluation of cell loss 
At the end of EEG recordings, mice were deeply anaesthetized using penthotal sodium 
(100 mg/kg, ip) and perfused via ascending aorta with 50 mM cold PBS (pH 7.4), followed 
by chilled 4% paraformaldehyde (PAF) in 50 mM PBS. The brains were post-fixed for 90 
min at 4°C, and then transferred to 20% sucrose in PBS for 24 h at 4°C, then rapidly 
frozen in –50°C isopentane for 3 min and stored at –80°C until assayed. Serial coronal 
sections (40 µm) were cut on a cryostat throughout the septal-temporal extension of the 
hippocampus (-0.94 to -3.64 mm from bregma) (Franklin and Paxinos, 2008) and collected 
in 0.1 M PBS. We prepared 12 series of 5 sections each (8 series including the septal and 
4 series including the temporal aspect of the hippocampus). In each series, the 1st and 2nd 
sections were stained for Nissl. The same anatomical structures were retained within each 
series of sections from control and respective experimental mice. Quantification analysis of 
cell damage was done by Nissl-staining in 4 slices in each mouse brain by two 
independent investigators blinded to the identification code of the samples as previously 
described (Balosso et al., 2008; Iori et al., 2013). High-power fields (20X magnification; 
Olympus) along the CA1 and CA3 pyramidal cell layers and the hilus were acquired. In 
each section, neuronal cell loss was quantified by measuring the area (µm2) occupied by 
Nissl-stained neurons in CA1 and CA3 pyramidal, and by reckoning the number of Nissl-
stained neurons in the hilus (Balosso et al., 2008; Iori et al., 2013). Data obtained in each 
slice/area/brain were averaged providing a single value for brain area/mouse, and this 
value was used for statistical analysis. Since the volume of the septal hippocampus 
(McDaniel et al, 2001) was similar in the experimental groups (sham, 8.7 ± 0.5 mm3, n=5; 
epileptic mice treated with negative control,  8.3 ± 0.3 mm3, n=7; epileptic mice treated 
with mimic, 7.9 ± 0.4 mm3, n=7), it is unlikely that cell loss quantification was affected by 
tissue shrinkage or major changes in extracellular space. The occurrence of any bias in 
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counting should similarly affect control and experimental samples since these samples 
underwent the same procedures in parallel.  
Western blot 
Mice were deeply anesthetized using penthotal sodium, then perfused via ascending aorta 
with 50 mM ice-cold PBS (pH 7.4) for 1 min to remove blood, and decapitated. The 
hippocampus ipsilateral to the injection of either mimic or antagomiR was rapidly dissected 
out at 4°C (n=8 each group). Tissue was homogenized (30 mg tissue/150 µl 
homogenization buffer) as previously described (Balosso et al., 2009). Total proteins (50 
µg per lane; Bio-Rad Protein Assay, Bio-Rad Laboratories, Munchen, Germany) were 
separated using SDS-PAGE 10% acrylamide, and each sample was run in duplicate. 
Proteins were transferred to Immobilon-P polyvinyldene difluoride (PVDF) membranes 
(Millipore BV, Amsterdam, Netherlands) by electroblotting. For immunoblotting, we used 
an anti-IRAK-2 (1:1000, Santa Cruz Biotechnology, Cat#sc-130788, Heidelberg, Germany) 
and anti-TRAF-6 (1:500, Abcam, Cat#ab33915, Cambridge, MA, USA) rabbit polyclonal 
antibodies. Immunoreactivity was visualized with enhanced chemiluminescence (ECL) 
using peroxidase-conjugated goat anti-rabbit (1:1000; Sigma, Cat#A0545) IgG as 
secondary antibody. Densitometric analysis of immunoblots was done by Quantity One 
software (Bio-Rad Laboratories) to quantify the changes in protein levels using film 
exposures with maximal signals below the photographic saturation point. Optical density 
values in each sample were normalized using the corresponding amount of β-actin 
(1:20000, Santa Cruz Biotechnology, Cat#sc-47778). 
In situ hybridization 
Mice were deeply anaesthetized using penthotal sodium (100 mg/kg, ip) and perfused via 
ascending aorta with 50 mM cold PBS (pH 7.4) followed by chilled 4% paraformaldehyde 
(PAF) in 50 mM PBS. The brains were post-fixed at 4°C. The hybridizations were done on 
5 µm sections of paraffin embedded materials, as previously described (Budde et al., 
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2008; Gorter et al., 2014; van Scheppingen et al., 2016). A 5’ fluorescein (FAM) labelled 
antisense oligonucleotide containing Locked Nucleic Acid (LNA; indicated with “I”) and 2'-
o-methyl modification (indicated with “m”) (5’FAM-
lAmAmClCmCmAlTmGmGlAmAmUlTmCmAlGmUmUlCmUmClA; Ribotask ApS, Odense, 
Denmark) was used. The probe was hybridized at 56o C for 1 h and the hybridization was 
detected with alkaline phosphatase (AP) labeled anti-fluorescein (Roche Applied Science, 
Basel, Switzerland). NBT (nitro-blue tetrazolium chloride)/BCIP (5-bromo-4-chloro-3'-
indolyphosphate p-toluidine salt) was used as chromogenic substrate for AP. Negative 
control assay was performed without probe (sections were blank). The images were 
captured with an Olympus microscope (BX41, Tokyo, Japan) equipped with a digital 
camera (DFC500, Leica Microsystems-Switzerland Ltd., Heerbrugg, Switzerland) and 
processed by Fiji (ImageJ2). In a first step, colour deconvolution (RGB colour space) was 
performed in order to separate positive cells from background according to the following 
channel parameters: red: 0.21408768, green: 0.8171735, blue: 0.4782719. Then a 
threshold (= 233) was applied and subsequently the images were converted to 8 bit gray-
scale. The positive pixels/total assessed pixels, indicated as staining percentage area was 
used for subsequent statistical analysis. For double-staining, combining in situ 
hybridization with immunocytochemistry, the sections were first processed for in situ 
hybridization, then for immunocytochemistry with monoclonal mouse GFAP (1:4000, 
Sigma, San Louis, Mo, USA) (Gorter et al., 2014). Signal was detected using the 
chromogen 3-amino-9-ethylcarbazole (Sigma-Aldrich). This methodology does not 
distinguish between endogenous miR-146a and the injected mimic. 
Real-time quantitative polymerase chain reaction analysis (RT-qPCR)  
Mice were deeply anesthetized using penthotal sodium, then perfused via ascending aorta 
with 50 mM ice-cold PBS (pH 7.4) for 1 min to remove blood, and decapitated. Hippocampi 
ipsilateral to the icv injection side were rapidly dissected out at 4°C in RNAse free 
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environment, immediately frozen on dry ice and stored at –80°C until assay. cDNA was 
generated using Taqman MicroRNA reverse transcription kit (Applied Biosystems) 
according to manufacturer’s instructions.  
Expression of miR-146a, miR-21, miR-155 and the U6B small nuclear RNA gene (rnu6b) 
were analysed using Taqman microRNA assays (Applied Biosystems), which were run on 
a Roche Lightcycler 480 thermocycler (Roche Applied Science, Basel, Switzerland) 
according to manufacturer’s instructions (Iyer et al., 2012). The PCR reactions were 
prepared using an automated pipetting system (epMotion 5075 Eppendorf) and each 
sample was run in triplicate. Quantification of data was performed using the computer 
program LinRegPCR in which linear regression on the Log(fluorescence) per cycle number 
data is applied to determine the amplification efficiency per sample (Ramakers et al., 
2003; Ruijter et al., 2009). Data were normalized on the expression levels of the 
housekeeping gene rnu6b.  
Extracellular recordings 
Postnatal day 21-28 mice were icv injected with PBS (n=8) or with 10 µg mimic or its 
negative control (n=5-7 mice/each group) under gas anaesthesia. One or 24 h after 
injection, mice were deeply anesthetized using penthotal sodium and decapitated. Coronal 
brain slices (350 µm; n=12 slices/each treatment group) were cut in ice-cold modified 
artificial cerebrospinal fluid (aCSF) containing the following (in mM): 87 NaCl, 2.5 KCl, 1 
NaH2PO4, 75 sucrose, 7 MgCl2, 24 NaHCO3, 11 D-glucose, and 0.5 CaCl2. Slices were 
then transferred into an incubating chamber and submerged in aCSF containing (in mM): 
130 NaCl, 3.5 KCl, 1.2 NaH2PO4, 1.3 MgCl2, 25 NaHCO3, 11 D-glucose, 2 CaCl2 and 
constantly bubbled with 95% O2 and 5% CO2 at room temperature. Slices were incubated 
in this condition for at least 1 h, then transferred in a submerged recording chamber, 
perfused with oxygenated aCSF at a rate of 2 ml/min and a constant temperature of 28-
30ºC. In a different set of PBS-injected mice (n=4 each group), slices (n=10-11/each 
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treatment group) were incubated with IL-1Ra (2 µg/ml) or Lps-Rs (100 ng/ml) for 60 min 
after the initial 60 min recovery time as well as during recordings. Extracellular recordings 
of population spikes (PS) were obtained in CA1 pyramidal layer using glass micropipettes 
filled with 3 M NaCl. Stimulation of Schaffer collaterals was delivered by a Constant 
Voltage Isolated Stimulator (Digitimer Ltd., Welwyn Garden City, UK) through bipolar 
twisted Ni/Cr stimulating electrode.PS amplitude was measured as the amplitude of the 
first negative deflection overriding the field EPSP waveform. The input-output curves were 
plotted as the relationship of PS amplitude versus stimulus intensity (2V steps). Four 
consecutive PS were averaged for each stimulus intensity. Data were amplified and 
filtered (low filter 10 Hz, high filter 3 kHz) by a DAM 80 ACDifferential Amplifier (World 
Precision Instruments, Sarasota, FL, USA), and digitized at 10 kHz by a Digidata 1322 
(Molecular Devices, Foster City, CA, USA). 
Statistical analysis 
Data are the mean ± s.e.m. (n=number of individual samples). Statistical analysis was 
done by Graph-Pad Software using absolute values. Two-group comparison was made by 
Mann-Whitney test (Fig. 1B,C,D; Fig. S2; Fig. S1A,B; Fig. S3D). The random-effects 
model (Borenstein et al., 2009) was used to estimate the frequency of spontaneous 
seizures (average number of seizures/day) followed by the DerSimonian and Laird method 
to estimate the variance among the average daily seizures. Two-group comparison was 
done by Chi-square test (Fig. 2 and Fig. 3). Multi-group comparison was done by Kruskal-
Wallis test (Fig. 1A) or by two-way ANOVA for repeated measures followed by Bonferroni 
post-hoc test (Fig. S2E). Two-sided statistical tests were used. Differences between 
groups were reported as statistically significant for values of p≤0.05. 
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RESULTS 
miR-146a forebrain levels are modulated by its oligonucleotide mimic or antagomiR 
Naive mice. We developed a treatment protocol for modifying the forebrain levels of miR-
146a (Fig. 1A,C) in naive mice for exploring if this intervention affects neuronal excitability 
(Fig. 1B,D; Fig. S1E). We used either a specific synthetic oligonucleotide analog of miR-
146a (mimic), or its antisense oligonucleotide (antagomiR), and their specific non-targeting 
scrambled oligonucleotides (negative controls) as control solutions. An icv injection of 10 
µg (0.7 nmol) in 1 µl of mimic (Lehmann et al., 2012) done in naive mice induced a 4-fold 
increase on average in hippocampal miR-146a levels measured 24 h later, then declining 
within 72 h (Fig. 1A). This increase approximates the 3- to 5-fold raise measured in the 
hippocampus during epileptogenesis in animal models, and in human epilepsy specimens 
(Aronica et al., 2010; Prabowo et al., 2015). miR-146a mimic injection did not affect other 
associated miRNAs (e.g., miR-21 and miR-155; Fig. S1D). Conversely, 24 h after the icv 
injection of 1.7 nmol antagomiR in naive mice, hippocampal miR-146a level were 
decreased by 50% on average (Fig. 1C). 
In situ hybridization histochemistry showed that 10 µg mimic significantly increased miR-
146a level in forebrain neurons of naive mice (Fig. S2, panels a-c vs d-f). No degenerative 
or glial cell reactive changes were observed. This mimic dose induced a decrease in 
hippocampal levels of two key proteins mediating the IL-1R1/TLR4 signaling, namely 
IRAK-2 and TRAF-6 (Fig. S1A,C), in accordance with previous evidence reporting that 
these proteins are the primary targets of this miRNA (Taganov et al., 2006; O'Neill, 2008; 
Boldin et al., 2011; Iyer et al., 2012; Zeng et al., 2013; van Scheppingen et al., 2016); a 
negative correlation was found between miR-146a and IRAK-2 or TRAF-6 levels (Fig. 
S1B). These results, therefore, show that mimic injection in naive mice reduces IRAK-2 
and TRAF-6 by increasing miR-146a levels in neurons (Fig. S2, panels a-f; quantification 
in p-r). 
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Status epilepticus (SE) exposed mice. Next, we injected the mimic or its negative control in 
SE-exposed mice when they developed the first two spontaneous seizures (i.e., after 
epilepsy onset) to determine the cell types showing the increase in miR-146a by in situ 
hybridization analysis. We used the same injection protocol designed to test mimic's 
therapeutic potential in the disease-modification study (Fig. S3B). We analyzed miR-146a 
cellular expression 24 h after the last mimic or negative control injection. In epileptic mice 
injected with the negative control, miR-146a levels were significantly increased in both 
neurons and astrocytes (arrowheads) compared to similarly injected sham mice (Fig. S2, 
panels g-i vs a-c). This finding is in accordance with previous evidence reporting the 
endogenous increase in miR-146a in these cell populations in a rat model of 
epileptogenesis (Aronica et al., 2010). In epileptic mice, mimic injection further augmented 
miR-146a levels (Fig. S2, panels j-l vs g-i) in both neurons and GFAP-positive astrocytes 
(Fig. S2, panels m-o). This injection protocol therefore enhanced the miR-146a levels in 
neurons and astrocytes of epileptic mice above those induced by the disease itself (Fig. 
S2, quantification in panels p-r).  
The dose of 10 µg mimic was used in the subsequent in vivo experiments (protocols in 
Fig. S3B and Fig. S4B,C).	
The modulation of miR-146a hippocampal level in naive mice affects neuronal 
excitability and acute seizures 
We examined whether changes in miR-146a forebrain levels in naive mice affect neuronal 
excitability and, as a consequence, their susceptibility to acute seizures. We injected naïve 
mice with either the 10 µg miR-146a mimic or 12 µg cumulative dose of its antagomiR, 24 
h before an intrahippocampal convulsive dose of kainic acid (Maroso et al., 2010), an 
agonist of glutamate receptors (protocol in Fig. S4B,C). The mimic significantly delayed 
the onset of acute seizures, and reduced their frequency and duration by approximately 
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50% (Fig. 1B). This effect was similar to that previously attained using specific IL-
1R1/TLR4 receptor antagonists in the same model (Vezzani et al., 2000; Vezzani et al., 
2002; Maroso et al., 2010; Maroso et al., 2011a). The effect of mimic on acute seizures 
persisted for 72 h (Fig. 1B), in the absence of a sustained increased in miR-146a level 
(Fig. 1A). The mimic did not affect seizures when injected 1 h or 7 days before kainic acid 
(Fig. 1B), likely reflecting the time required for signal proteins (IRAK-2, TRAF-6) 
downregulation (Iyer et al., 2012) and their re-synthesis after miR-146a returned to 
baseline level (Fig. 1A). The injection of 5 µg mimic was ineffective on seizures (number of 
seizures, mimic: 6.5 ± 0.2; negative control, 6.7 ± 0.3; time spent in seizures, mimic: 5.5 ± 
0.2; negative control, 5.6 ± 0.3; n=6 mice each group).  
The mimic (10 µg) also significantly decreased seizures in mice intrahippocampally 
injected with bicuculline (Vezzani et al., 2000; Maroso et al., 2010), a GABAA receptor 
blocker: number of seizures (mimic, 3.7 ± 0.3; negative control, 7.8 ± 0.3); time spent in 
seizures (mimic, 1.7 ± 0.3; negative control, 5.2 ± 0.3 min) and delayed seizure onset 
(mimic, 11.4 ± 1.0; negative control, 7.2 ± 0.6 min) (n=10 mice each group, p<0.01 by 
Mann-Whitney test). Thus, the effect of mimic was independent of the convulsive drug 
triggerring seizures. Overall, these findings predict that knock-down of endogenous miR-
146a by its antagomiR should increase seizures. In accordance, the antagomiR mediated 
a significant increase in seizure number and duration, and accelerated  the time to seizure 
onset (Fig. 1D). 
The inhibitory effect of mimic on acute seizures is an indicator of reduced neuronal 
excitability, therefore, we tested this idea in acute hippocampal slices prepared from mice 
injected 24 h before with either 10 µg mimic- or its negative control. Schaffer collaterals 
were stimulated and population spike amplitude was measured in stratum pyramidale CA1 
(Fig. S1E). Slices from mimic-injected mice showed a right shift of the input-output curve 
(population spike amplitude vs stimulus intensity) compared to control slices, showing that 
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neuronal excitability was reduced. A similar shift was observed in hippocampal slices 
obtained from naive mice after 1 h pre-incubation with either Lps-Rs (100 ng/ml) or IL-1Ra 
(2 µg/ml), antagonists of TLR4 and IL-1R1 (Vezzani et al., 2000; Vezzani et al., 2002; 
Maroso et al., 2010), respectively. Overall, these data demonstrate that miR-146a mimic 
induces a decrease in both hippocampal excitability and acute seizures by inhibiting the 
IL-1R1/TLR4 signaling in neurons via a reduction of key signal transduction proteins. 
miR-146a mimic arrests epilepsy progression and decreases chronic seizures in a 
mouse model of acquired epilepsy 
To determine whether miR-146a mimic interferes with epilepsy course, we studied mice 
developing spontaneous seizures after SE provoked by intra-amygdala kainate injection 
(Shinoda et al., 2004; Li et al., 2008; Mouri et al., 2008; Jimenez-Mateos et al., 2012; Liu 
et al., 2013; Gu et al., 2015) (Fig. S3A-C). This is a widely used model of acquired 
epilepsy induced by SE (Shinoda et al., 2004; Li et al., 2008; Mouri et al., 2008; Liu et al., 
2013; Gu et al., 2015), an acute and severe inciting event that causes epilepsy in humans 
(Tsai et al., 2009; Rossetti et al., 2013; Harward and McNamara, 2014; Vezzani et al., 
2015a). Either the mimic or its negative control was injected in two randomized cohorts of 
electrode-implanted SE-exposed mice under continuous video-EEG monitoring (Fig. 2). 
Mice were exposed to SE of similar severity and duration (Fig. S3C). At the onset of 
epilepsy in each mouse (i.e., after the occurrence of the first two spontaneous seizures), a 
total of five injections of either 10 µg mimic or its negative control were done, each 
injection was given every 72 h, then treatment was stopped (protocol in Fig. S3B). This 
repetitive injection protocol was designed for mantaining therapeutic levels of mimic for 2 
weeks, as suggested by the evidence that its inhibitory effect on acute seizures lasts for 
72 h then elapsing by 7 days after the last administration (Fig. 1B and Fig. S3D). This set 
of evidence supports that the mimic is cleared from the brain tissue within one week after 
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the last injection, thus supporting that our injection protocol allows to test potential 
disease-modification effects of the treatment (i.e. a therapeutic effect overlasting the 
presence of the mimic in the tissue). 
As expected by the natural history of the disease in this model (Fig. 2A, n=15; Fig. S3B, 
n=26), negative control-injected mice showed an average 3-fold progression in the 
frequency of spontaneous seizures over 2.5 months of video-EEG monitoring from the 
onset of epilepsy. Seizure progression was prevented in mice treated with miR146a mimic 
compared to negative control-injected mice (Fig. 2B vs A). Overall, at 2.5 months from 
disease onset, the mimic-treated mice showed a 80% reduction on average in the number 
of seizures compared to control mice (p<0.01 by Chi-square test, n=15 mice each group), 
and 50% regression in seizure frequency compared to seizures at the beginning of the 
disease (i.e., the first 16 days from disease onset; p<0.01 by Chi-square test) (Fig. 2B). 
Accordingly, the maximal inter-seizure interval measured between 2.0 and 2.5 months was 
about 4-fold longer in mimic-treated mice (7.2 ± 1.1 day, n=15, p<0.01 by Mann-Whitney 
test) vs control mice (1.7 ± 0.3 day). The average seizure duration was increased in 
negative control-injected mice at 2.5 months (51.4 ± 1.8 sec, p<0.01 by Mann-Whitney 
test) compared to disease onset (40.2 ± 2.3 sec), and this parameter was not affected by 
the mimic.  
The extent and pattern of cell loss in the hippocampus of mimic-treated mice was not 
different from control mice, as assessed in Nissl-stained sections in mice killed at 2.5 
months after the end of EEG recordings (negative control, 24±5% (n=7); mimic, 16±2% 
(n=7) reduction in hippocampal CA1 pyramidal neurons vs sham mice (n=5); negative 
control, 18±4%; mimic, 17±5% reduction in hippocampal CA3 pyramidal neurons vs sham 
mice; negative control, 32±7%; mimic, 26±4% reduction in hilar neurons sham mice). This 
is conceivable considering that cell loss mostly develops within one week from the 
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induction of SE therefore before the treatment was applied to mice (Mouri et al., 2008; Noé 
et al., 2013).  
Antiinflammatory drugs blocking IL-1R1/TLR4 signaling reproduce the mimic 
therapeutic effects 
We studied whether drugs blocking the IL-1R1/TLR4 signaling prevent seizure progression 
and induce seizure remission, as shown by the mimic intervention. We used the clinically 
tested drug VX-765 (a selective inhibitor of Interleukin Converting Enzyme which blocks IL-
1β biosynthesis and HMGB1 release) (Wannamaker et al., 2007; Maroso et al., 2011a; 
Keyel, 2014) and the investigational drug Cyanobacterial LPS (CyP, an antagonist of 
TLR4) (Macagno et al., 2006; Maroso et al., 2010) (Fig. 3A,B). We combined these drugs 
(doses and treatment schedule are reported in Fig. S3B and legend) for attaining efficient 
and simultaneous blockade of the IL-1R1 and TLR4 signaling. In fact, we showed 
previously that inhibition of IL-1R1 signaling in a rat model of epileptogenesis is not 
sufficient to prevent TLR4 receptor activation (Noé et al., 2013) which contributes itself to 
spontaneous seizures generation (Iori et al., 2013). This drug combination was given daily 
for one week starting at the time of epilepsy onset in each mouse, then the treatment was 
stopped and mice were followed up for the next 2.5 months. Drugs prevented seizure 
progression and reduced by 90% on average spontaneous seizure frequency as 
compared to vehicle-injected mice (Fig. 3A,B). Moreover, drug-treated mice showed an 
average 70% regression in chronic seizure frequency compared to their seizure baseline 
at beginning of the disease (Fig. 3B).  
Overall, the data show that transient blockade of the IL-1R1/TLR4 pathway after epilepsy 
onset using two complementary treatment approaches (namely, mimic or antiinflammatory 
drugs) significantly improves the clinical course of the disease by drastically reducing 
spontaneous seizure recurrence by 80-90%. Animals did not show any behavioral sign of 
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toxicity during either epigenetic or drug treatment, as assessed by visual observation of 
their motor activity and behavioral reactivity to touch or tail pinching in the recording cage. 
Body weight growth also did not differ among the various experimental groups at the end 
of treatment (mimic, 27.4 ± 0.6 g, n=15; VX-765+CyP, 27.7 ± 0.7 g, n=11; vehicle, 27.8 ± 
0.6 g, n=26; sham, 28.1 ± 0.7 g) and in the chronic epilepsy phase (mimic, 29.9 ± 0.9; VX-
765+CyP, 31.7 ± 0.6; vehicle, 29.5 ± 0.5; sham, 32.5 ± 0.7) as compared with their 
respective body weight before treatment was started (mimic, 27.1 ± 0.5; VX-765+CyP, 
26.7 ± 0.6; vehicle, 27.5 ± 1.1; sham, 27.7 ± 0.2).  
Next, we studied whether targeting of the IL-1R1/TLR4 signaling represents an 
improvement over current AED treatment options (Fig. 3C). We tested different doses of 
carbamazepine (CBZ), an AED of choice in the clinical setting (Iyer and Marson, 2014). 
CBZ was given in food pellet at different concentrations of 2.5, 5.0, 10.0 mg/g pellet for 2 
weeks to naive mice to attain steady-state plasma levels within the therapeutic range 
during the treatment period. Considering that CBZ-in-food daily intake in naive mice was 
4.3 g on average (Fig.S5A), the corresponding dose of CBZ in each treatment group was 
about 10, 20, 40 mg CBZ daily/mouse, respectively. As shown in Fig. S5C, plasma levels 
of CBZ+CBZ-E were within therapeutic range using 5.0 and 10.0 mg/g CBZ pellet (4-10 
µg/ml; in accordance with Ali et al., 2012; Burianova and Borecka, 2015). Since 10 mg/g 
CBZ provoked loss of body weight during treatment (Fig. S5B), we choose the dose of 5 
mg/g CBZ-in-food (maximal tolerated dose) for the experiments in Fig. 3C. Epileptic mice 
consumed CBZ-in-food for 2 weeks starting after disease onset in each mouse (Fig. S3B) 
and their daily intake (~4.2 g) was was similar to naive mice. Treatment did not prevent 
seizure progression nor reduced seizure frequency in chronic epileptic mice as compared 
to their seizure frequency at disease onset (Fig. 3C) or vs vehicle controls (Fig. 3A). 
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DISCUSSION 
 This study identifies treatments with clinically relevant therapeutic effects based on 
disease modification in a mouse model of acquired epilepsy. These effects are attained by 
a transient inhibition of the IL-1R1/TLR4 signaling in forebrain using either epigenetic or 
pharmacological approaches. In particular, we found that treatment with a synthetic miR-
146a mimic, which inhibits IL-1R1/TLR4 intracellular signaling (Aronica et al., 2010; Quinn 
and O'Neill, 2011; Iyer et al., 2012; van Scheppingen et al., 2016), or with a combination of 
drugs which prevent IL-1β biosynthesis and block TLR4 (Macagno et al., 2006; 
Wannamaker et al., 2007; Maroso et al., 2010; Maroso et al., 2011a; Keyel, 2014), arrests 
the progression of epilepsy in mice and reduces spontaneous chronic seizures up to 90% 
as compared to the natural history of disease in control mice. This is a highly relevant 
clinical endpoint considering that 50% seizure reduction determines meaningful drug 
efficacy in patients (Mohanraj and Brodie, 2003). These two approaches result in strikingly 
similar outcomes, thus providing the first preclinical evidence of a genuine disease 
modification effect in an animal model of acquired epilepsy. Notably, treatments were 
initiated after the onset of spontaneous seizures in each mouse, in order to mimic a 
clinically feasible intervention in patients with diagnosed epilepsy. Although the therapeutic 
agents were transiently applied for 1 to 2 weeks, a dramatic regression in spontaneous 
seizures occurred at the end stage of the disease, i.e., 2.5 months after epilepsy onset, 
and this effect was measurable already 1.5 months after the end of treatment, when the 
injected agents were cleared from the tissue. Moreover, none of the agents modified the 
early spontaneous seizures during treatment possibly due to the concomitant occurrence 
of various pathogenic mechanisms triggered by SE, in addition to neuroinflammation, that 
significantly contribute to ictogenesis at the beginning of the disease (first 2 weeks from 
disease onset). This is at variance with the prominent anticonvulsive effects of 
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antiinflammatory treatments on acutely evoked seizures in naive mice (this study; Maroso 
et al, 2010; Maroso et al, 2011a; Ravizza et al, 2006), or in chronic epileptic animals 
(Maroso et al, 2010; Maroso et al, 2011a), suggesting that neuroinflammation is a 
predominat mechanism of ictogenesis in these conditions.  This set of evidence excludes 
therefore that the long-term reduction in spontaneous seizures merely reflects a 
symptomatic treatment effect and indicates that the interventions have modified the 
epileptogenic network, thereby preventing disease progression. 
The clinical relevance of our findings is underlined by the lack of disease-modification 
effects of CBZ, a classical AED widely used for the symptomatic control of seizures in 
human epilepsy (Mohanraj and Brodie, 2003), thus supporting the clinical evidence that 
AEDs do not affect epileptogenesis (Temkin, 2001).  
Our data indicate that the therapeutic effects attained by inhibition of the IL-1R1/TLR4 
signaling relate to reversal of neuronal hyperexcitability provoked by receptor activation by 
IL-1β and HMGB1 that are released during epileptogenesis. Accordingly, the activation of 
IL-1R1/TLR4 signaling by these two endogenous ligands enhances seizure susceptibility 
in animal models (Vezzani et al., 2000; Vezzani et al., 2002; Maroso et al., 2010; Maroso 
et al., 2011a; Iori et al., 2013). Moreover, we found that naive mice treated with miR-146a 
mimic, or hippocampal slices exposed to IL-1R1/TLR4 antagonists, displayed decreased 
intrinsic neuronal excitability that was associated with a reduced propensity to generate 
seizures. This effect is due to IRAK/TRAF6 mediated signaling inhibition in neurons where 
miR-146a is increased following mimic treatment. We previously described that the pivotal 
mechanism involved in IL-1R1/TLR4 modulation of neuronal excitability and seizures relies 
upon increased neuronal calcium influx via ceramide/src kinase-mediated phosphorylation 
of the NR2B-expressing NMDA receptors (Viviani et al., 2003; Balosso et al., 2008; Iori et 
al., 2013; Balosso et al., 2014). Increased pre-synaptic calcium leading to glutamate 
release (Pedrazzi et al., 2012) is also likely involved in the hyperexcitability mediated by 
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signaling activation. Although activation of IL-1R1/TLR4 has been implicated in cell loss 
(Viviani et al., 2003; Balosso et al., 2014), we did not detect neuroprotection in the 
hippocampus of mimic-treated mice although spontaneous seizures were drastically 
reduced. This result is compatible with evidence that cell loss is mostly completed within 
the first week after SE induction (Mouri et al., 2008); we cannot exclude therefore that 
intervention before spontaneous seizures arise may be neuroprotective.  
The IL-1R1/TLR4 signaling is classically described as a pivotal trigger of the inflammatory 
cascade (Quinn and O'Neill, 2011; Keyel, 2014), and glial cells expressing IL-1R1 or TLR4 
are chiefly involved in promoting and sustaining neuroinflammation in epilepsy (Aronica et 
al., 2012; Devinsky et al., 2013). Moreover, increased miR-146a in human astrocytes was 
shown to blunt IL-1R1/TLR4 mediated release of inflammatory cytokines (Iyer et al., 2012; 
van Scheppingen et al., 2016). It is therefore conceivable that inhibition of this signaling in 
glia, either due to the increased miR146a levels in astrocytes or to glial receptor blockade 
by our drugs, led to a reduction of downstream inflammatory effector molecules thereby 
contribute to the observed therapeutic outcomes (Vezzani, 2015).   
IL-1R1/TLR4 signaling is activated in various structural/lesional forms of human epilepsy 
that are often associated with a worse prognosis and with the development of 
pharmacoresistant seizures (Pitkanen and Sutula, 2002; Schmidt and Sillanpaa, 2005; 
Sarkis et al., 2012). This patient population may represent the elective target for 
treatments that inhibit the IL-1R1/TLR4 pathway. Although epigenetic intervention in 
human CNS diseases have not been attempted as yet, there is an intensive research for 
delivering biologics directly into the seizure focus or intrathecally, or via nasal spray 
preparation, to improve both therapeutic index and brain penetration (Yi et al., 2014). 
Some of these approaches are already applied to deliver drugs into the human CNS, 
particularly for brain tumors or pain. In principle, these interventions, together with 
chemical modifications to prolong the mimic half-life, might be considered for clinical 
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translation of miRNA-based therapeutic strategies in epilepsy (see also Lee et al, 2016; 
Yuan et al, 2016). A more prompt translation, however, can be envisaged using drugs 
blocking the IL-1R1/TLR4 signaling, such as VX-765 and anakinra (Kenney et al., 2016; 
Bialer et al., 2013; Jyonouchi and Geng, 2016), which have been already tested in 
humans with clinical signs of efficacy and safety profile (see also Leon et al., 2008; Lepper 
et al., 2010).  
In summary, our findings provide the first proof-of-concept evidence for disease-
modification in epilepsy using specific interventions transiently applied after disease onset. 
The data show that the burden of seizures can be drastically reduced by targeting 
disease-relevant mechanisms. This is a novel therapeutic approach for epilepsy as 
compared to chronic administration of AEDs which mainly provide a symptomatic control 
of seizures. 
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Figure 1. Modulation of miR-146a hippocampal level affects acute seizures 
(A) RT-qPCR measurement of miR-146a in mouse hippocampus 24 or 72 h after a single 
icv injection of 10 µg (0.7 nmol) of either mimic or its negative control (n=8 each group). 
(B) Seizures parameters in mice injected with 10 µg mimic or its negative control (n=6-10 
each group) 1, 24, 72 h or 7 d before kainic acid. The bargram reports pooled control data 
from the different time points since they did not differ (n=34). (C) RT-qPCR measurement 
of miR-146a in mouse hippocampus 24 h after daily icv injection of 1 µg (0.28 nmol) 
antagomiR or its negative control for 6 days (n=10 each group). (D) Seizures parameters 
in mice injected icv with antagomiR or its negative control followed by kainic acid (n=9 
each group). Data are mean ± s.e.m.; *p<0.05, **p<0.01 vs negative control by Kruskal-
Wallis (A) or Mann-Whitney (B,C,D) test. 
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Figure 2. miR-146a mimic injection after epilepsy onset prevents disease progression and 
reduces chronic seizures in mice 
Average daily seizures in negative control- (A) and mimic-injected mice (B) during day 1-
16 and day 45-74 from epilepsy onset (onset day, negative control, 5.5 ± 0.4, n=15; mimic, 
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5.3 ± 0.4, n=15). Icv injections were done at days 1,4,7,10 and 13 from disease onset, 
according to protocol in Fig. S3B. Seven mice out of 15 mice in each group were recorded 
in the hippocampus ipsilateral to the kainate-injected amygdala and in the contralateral 
overlying cortex, between days 1-16 and days 60-74. The remaining eight mice in each 
group were recorded in the injected amygdala and the ipsilateral hippocampus, from days 
1-16 and days 45-74. Since these two cohorts of mice shared the hippocampal site of 
recording and displayed a similar number of daily seizures during the common recording 
periods (days 1-16 and days 60-74; Chi-square test), they were pooled together. Notably, 
EEG seizures simultaneously occurred at all sites of recordings and they were always 
associated with generalized motor convulsions, and similarly affected by the treatment.  
Data (mean ± s.e.m.) were analyzed by Chi-square test; *p<0.01 vs respective seizure 
frequency during days 1-16; °p<0.01 vs seizure frequency during days 45-74 in negative 
control-treated mice (B vs A).  
Mean and 95% confidence interval (CI): (A) days 1-16: 1.05 (CI 0.85-1.25), days 45-74: 
5.38 (CI 4.79-5.96); (B) days 1-16: 1.01 (CI 0.76-1.26), days 45-74: 0.37 (CI 0.27-0.47); 
difference of mean values during days 45-74 (B vs A): 4.79 (CI 4.20-5.38). 
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Figure 3. Pharmacological treatment with VX-765 and Cyanobacterial LPS (Cyp), but not 
with carbamazepine (CBZ), after epilepsy onset prevents disease progression and 
reduces chronic seizures in mice 
	 36	
Average daily seizures in vehicle- (A) and drug-injected mice (B) during day 1-9 and day 
45-74 from disease onset (onset day: vehicle, 4.9 ± 0.5, n=11; VX-765+CyP, 5.1 ± 0.5, 
n=11). VX-765 (100 mg/kg, i.p.) and Cyp (1 mg/mouse, i.p.) were given daily for 7 days 
from disease onset to block the activation of the IL-1R1/TLR4 signaling, then treatment 
was stopped (protocol in Fig. S3B). (C) Average daily seizures during day 1-16 and day 
45-74 from disease onset (5.5 ± 0.9 days, n=7) in CBZ-treated mice. Mice were treated 
with CBZ-in-food during day 1-14 from epilepsy onset (protocol in Fig. S3B). Placebo pellet 
given to epileptic mice for 2 weeks did not modify their spontaneous seizure frequency, as 
assessed by continuous EEG monitoring (2.7 ± 0.6 seizures/day in mice fed with placebo 
pellet vs 3.3 ± 0.8 seizures/day in mice fed with a normal diet, n=7 each group). We 
therefore used the cohort of vehicle-injected mice fed with a normal diet (panel A) for 
cross-sectional comparison with mice fed with CBZ-in-food (panel C) since these two 
cohorts were run in parallel with experimental mice in panel B.   
Data (mean ± s.e.m.) were analyzed by Chi-square test; *p<0.01 vs seizure frequency 
during drug- or vehicle-injection; °p<0.01 vs seizure frequency during days 45-74 in 
vehicle-injected mice (B vs A).  
Mean and 95% confidence interval (CI): (A) days 1-9: 0.64 (CI 0.45-0.82), days 45-74: 
2.86 (CI 2.30-3.43); (B) days 1-9: 0.74 (CI 0.40-1.08), days 45-74: 0.23 (CI 0.16-0.29); (C) 
days 1-16: 0.18 (CI 0.08-0.28), days 45-74: 2.01 (CI 1.73-2.28); difference of mean values 
during days 45-74 (B vs A): 2.54 (CI 1.98-3.11). CBZ-treated mice showed a 3-fold higher 
seizure frequency compared to VX-765+CyP-treated mice during days 45-74 after disease 
onset (p<0.01 by Chi-square test) while they did not differ from vehicle controls (A). 
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SUPPLEMENTARY MATERIALS 
Fig. S1. Hippocampal level of IRAK-2 and TRAF-6 proteins and hippocampal level of miR-
21 and miR-155 after miR-146a mimic or negative control injection and the associated 
reduction in hippocampal excitability in naive mice 
Fig. S2. In situ hybridization analysis of miR-146a in forebrain  
Fig. S3. Experimental model of SE-induced epilepsy and related injection protocols 
Fig. S4. Experimental model of acute seizures and related injection protocol in naive mice 
Fig. S5. Carbamazepine (CBZ)-in-food intake and corresponding plasma levels in naive 
mice 
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Fig. S1. Hippocampal level of IRAK-2 and TRAF-6 proteins (A-C) and hippocampal 
level of miR-21 and miR-155 (D) after miR-146a mimic injection and the associated 
reduction in hippocampal excitability (E) in naive mice  
(A,C) Western blot analysis of IRAK-2 and TRAF-6 protein level in the hippocampus, 24 h 
after a single injection of 10 µg of miR-146a mimic or its negative control in naïve mice 
(n=8 each group; p<0.05 by Mann-Whitney test), and their correlation with hippocampal 
miR-146a level (B) (r=Spearman correlation coefficient). Data (mean ± s.e.m) are 
expressed as relative changes compared to negative control value (arbitrary unit). (D) RT-
qPCR measurement of miR-21 and miR-155 in mouse hippocampus 24 h after single icv 
injection of 10 µg of either mimic or its negative control (n=8 each group). (E) Graph 
reports CA1 pyramidal neurons population spike (PS) amplitudes in response to increasing 
stimulation intensities of afferent Schaffer collaterals. Acute hippocampal slices were 
obtained from naïve mice 24 h after a single icv injection of 10 µg of either negative control 
(Control) or mimic (n=12 slices from 5-7 mice/each group). A set of acute slices were 
obtained 24 h after icv PBS injection in mice, and exposed to Schaffer collateral 
stimulation after 1 h pre-incubation with PBS, Lps-Rs (100 ng/ml) or IL-1Ra (2 µg/ml) 
(n=10-11 slices from 4 mice/each group), selective antagonists of TLR4 and IL-1R1 
(Maroso et al., 2010; Vezzani et al., 2000; Vezzani et al., 2002), respectively. Control 
(includes PBS injected mice since they did not differ from negative control mice) vs mimic 
F1.418=90.48, p<0.01; Control vs Lps-RS, F1,380=71.17, p<0.01; Control vs IL-1Ra, 
F1.399=133.8, p<0.01, by two-way ANOVA for repeated measures followed by Bonferroni 
post-hoc test. Bracket includes the values (in the range of stimulation between 20 and 30 
V) in the treatment groups with a significant difference vs Control (p<0.05 and p<0.01). PS 
amplitudes (mean ± s.e.m.) are normalized to the maximal value. Top raw depicts 
representative traces of PS in control, mimic, Lps-Rs and IL-1Ra groups at the stimulation 
intensity of 24 V. 
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Fig. S2. In situ hybridization analysis of miR-146a in forebrain after mimic injection 
Representative photomicrographs showing miR-146a in situ hybridization signal in 
basolateral amygdala (BLA), frontoparietal cortex (FrPaCtx) and CA1 subfield of the 
hippocampus, 24 h after a single icv injection of 10 µg negative control or miR-146a mimic 
in sham mice (implanted with cannula and electrodes but not exposed to SE; n=5 each 
group; panels a-f), or after 5 repetitive injections of 10 µg each in SE-exposed mice (one 
injection every 3 days, starting the day of epilepsy onset in each mouse, panels g-o; 
protocol in Fig. S3B) (n=4-5 each group).  Scale bar: 20 µm (a-l); 30 µm (m-o). Bargrams 
represent the percent area occupied by miR-146a signal in the respective brain areas 
(mean ± s.e.m.; n=4-5 mice each group; 2 slices/mouse). *p<0.05, **p<0.01 vs Sham + 
Negative control; #p<0.01 vs  SE + Negative control by Mann-Whitney test.  
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Fig. S3. Experimental model of SE-induced epilepsy and related injection protocols 
(A) Brain atlas plate depicting kainic acid (KA, 0.3 µg in 0.2 µl) injection site (black arrow) 
and adjacent EEG depth electrode placement (green line) in the right basolateral 
amygdala (BLA). The electrode positioning in the ipsilateral dorsal hippocampus is the 
same as depicted in Fig. S4A (green line). The schematic skull reproduction shows 
surface electrode placement (green circles) and the position of the guide cannula for 
intraamygdala KA injection (black circle). Representative EEG tracings depicting typical 
spontaneous seizures (and their respective baseline tracings) in two different mice. One 
mouse was recorded in injected amygdala and ipsilateral hippocampus while the other 
mouse was recorded in the hippocampus (ipsilateral to injected amygdala) and the 
contralateral overlying cortex. CTX, cortex, contralateral to the injection; RHP, right 
hippocampus, ipsilateral to the injection. These recordings show that EEG seizures 
simultaneously occur in hippocampus, cortex and injected amygdala. This ictal activity was 
always associated with generalized motor convulsions. EEG seizures were never recorded 
in electrode-implanted mice (not injected with kainate) undergoing long-term EEG 
recordings. (B) Mice were prepared as described in the Materials and Methods for SE 
induction and EEG recording. In each mouse, continuous EEG recording (24/7) was done 
from SE induction until epilepsy onset which is denoted as day 1 (i.e., the occurrence of 
two spontaneous seizures at least 48 h apart from SE induction). At day 1, mice were 
randomized in control and treatment groups. Bargram depicts the number of daily seizures 
(mean ± s.e.m.) in control mice (cumulative data from negative control-injected mice, 
n=15, Fig. 2A and vehicle-injected mice, n=11; Fig. 3A). We pooled the data to show the 
natural history of the disease in this model since the control groups did not differ (Mann-
Whitney test). Mimic- or drug-treated mice were EEG recorded (24 h/day) during treatment 
(each treatment schedule is reported in panel B), and from day 45 or day 60 to day 74 
from epilepsy onset (24/7). They were injected as follows: one cohort received 10 µg of 
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either negative control (n=15) or mimic (n=15) at day 1, then again at day 4, day 7, day 10 
and day 13 (red arrows; these mice are reported in Fig. 2). This treatment schedule was 
chosen based on pharmacodynamic measures reported in Fig. 1B and Fig. S3D, showing 
that the effect of mimic on hippocampal excitability lasts for at least 72 h after injection, 
then elapsing at one week. A different cohort of mice was treated for one week with daily 
injections of VX-765 (100 mg/kg, i.p.) and CyP (1 mg/mouse, i.p., injected 6 h after VX-
765) (Fig. 3A,B) following a treatment schedule based on pharmacokinetic data (Cyp, half-
life in blood 15 h; single daily repeated administration of VX-765 allows adequate systemic 
exposure to the active metabolite (Wannamaker et al., 2007) attaining therapeutic effective 
concentration in brain). We did not prolong treatment over one week to avoid exposing 
mice to many repetitive i.p. injections. The last cohort of mice was administered with CBZ-
in-food (20 mg/daily/mouse) for 2 weeks to reach steady-state therapeutic plasma levels at 
maximal tolerated doses (Fig. S5; Fig. 3C). (C) Temporal spike distribution during SE 
induced by intra-amygdala KA injection in mice subsequently randomized after the onset 
of epilepsy to control or treatment groups (panel B). Data from negative control- or vehicle-
injected mice were pooled together since SE did not differ (Mann-Whitney). Each point 
represents the cumulative number of spikes during progressive 1 h intervals. Curves did 
not differ among each other (by one-way ANOVA). (D) Effect of negative control or mimic 
repetitive icv injections (protocol in Fig. S4C) on acute seizures induced in naive mice by 
intrahippocampal KA injected 24 h or seven days after the last icv oligonucleotide injection. 
This result was used as a pharmacodynamic measure of the mimic clearance from brain 
tissue. *p<0.05; **p<0.01 vs negative control by Mann-Whitney test. 
 
 
	 8	
 
 
Fig. S4. Experimental model of acute seizures and related injection protocol in naive 
mice 
(A) Brain atlas plate depicting kainic acid (KA, 7 ng/0.5 µl) or bicuculline (51 ng/0.5 µl) 
unilateral injection site (black arrow) and the depth bipolar recording electrode that was 
placed in the hippocampus (green line) bilaterally. Schematic skull reproduction shows 
surface electrode placement (green circles) and the position of the guide cannula for 
intrahippocampal injection of convulsive drugs (black circle). Representative EEG tracings 
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depicting baseline recordings (top) and ictal activity after KA injection (bottom) 
simultaneously occurring in the left (LHP) and right (RHP) hippocampus in freely moving 
mice. (B) Mice received one icv injection (ipsilateraly to KA or bicuculline injection) of 10 
µg mimic or its negative control (red arrow) at different times (i.e., 1 h, 24 h, 72 h or 7 
days) before KA, or 24 h before bicuculline or their vehicle (black arrow). (C) Mice received 
five icv injection (one injection every 3 days, red arrows) of 10 µg mimic or its negative 
control, then 24 h (day 13) or one week (day 19) after the last icv injection they were 
intrahippocampally injected with KA. 
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Fig. S5. Carbamazepine (CBZ)-in-food intake and corresponding plasma levels in 
naive mice 
We used CBZ-in-food in order to attain steady-state therapeutic drug levels over 2 weeks 
because AEDs have a very short half-life in mice after their systemic delivery. Table in (A) 
reports the daily food intake in mice under a normal diet or fed with various doses of CBZ-
in-food for 2 weeks (n=4-6 each group), and their corresponding body weight (B). Note 
that a deflection in body weight was observed in mice fed with 10 mg/g CBZ denoting 
signs of toxicity. (C) Concentration of CBZ, and its active metabolite CBZ-epoxide (CBZ-
E), in plasma of mice after 2 weeks of feeding with the various CBZ-in-food 
concentrations. Plasma levels of CBZ+CBZ-E within therapeutic range (4-10 µg/ml; Ali et 
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al., 2012) were attained with CBZ doses of 5 mg/g and 10 mg/g of pellet. Since 10 mg/g 
provoked loss of body weight, we choose 5 mg/g CBZ-in-food (maximal tolerated dose) for 
the experiments in Fig. 2C: CBZ-in-food daily intake in epileptic mice was of 4.2 g. 
Estimation of CBZ and CBZ-E was done in plasma from blood collected from heart atrium 
in deeply anaesthetized mice, using high performance liquid chromatography (HPLC) with 
a UV diode array detector as previously described (Ali et al., 2012).  
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